Prostate cancer (PCa) is a leading cause of cancer-related death of men globally. Since its
introduction, there has been intense debate as to the effectiveness of the prostate specific …

Prostate cancer is a significant public health burden and a major cause of morbidity and
mortality among men worldwide. Analyzing geographic patterns and temporal trends may …

Current diagnosis and treatment stratification of patients with suspected prostate cancer
relies on a combination of histological and magnetic resonance imaging (MRI) findings. The …

Background In the UK, a man's lifetime risk of being diagnosed with prostate cancer is 1 in 8.
We calculated both the lifetime risk of being diagnosed with and dying from prostate cancer …

Objective: The objective of this study is to validate if ex-vivo multispectral photoacoustic (PA)
imaging can differentiate between malignant prostate tissue, benign prostatic hyperplasia …

Castration-refractory prostate cancer (CRPC) is treated with taxane-based chemotherapy,
but eventually becomes drug resistant. It is thus essential to identify novel therapeutic targets …

BACKGROUND Loss of the phosphatase and tensin homolog (PTEN) tumor suppressor
gene is a promising marker of aggressive prostate cancer. Active surveillance and watchful …

Materials and methods: The aim of the present pilot study was to study the association
between NK cell activity (NKA) and prostate cancer using a simple blood test. Subjects that …

Mitochondria (mt) encoded respiratory complex‐I (RCI) mutations and their pathogenicity
remain largely unknown in prostate cancer (PCa). Little is known about the role of mtDNA …

Prostate cancer represents the most encountered urinary malignancy in males over 50 years
old, and the second most diagnosed after lung cancer globally. Digital rectal examination …